MicroRNAs: Potential Targets in Diabetic Retinopathy

Abstract

Diabetic retinopathy (DR), a serious microvascular complication of diabetes, is a leading cause of blindness in adults. The pathogenesis of DR involves a variety of tissues and complex mechanisms, such as inflammation, oxidative stress, optic neurodegeneration, and autophagy. Nowadays, microRNAs (miRNAs), a novel group of non-coding small RNAs, have been extensively studied and recognized to play a key role in the pathogenesis of DR through aforementioned pathways. Furthermore, some miRNAs have been proposed as biomarkers that may be utilized to screen for DR. Also, miRNAs are a new therapy for DR. In this review, we summarize several miRNAs and, their roles in the pathogenesis of DR. miRNAs, as potential pharmacological targets for the diabetic retinopathy, may provide new insights for the treatment of DR.

Key words

microRNAs - diabetic retinopathy - biomarker - oxidative stress - inflammation - angiogenesis

• References

• 1 Yu J, Su W, Zhang X. et al. MicroRNAs in type 2 diabetes mellitus: Important for the pathogenesis but uncertain as biomarkers. J Diabetes. 2018;
• 2 Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297
• 3 Barutta F, Bellini S, Mastrocola R. et al. MicroRNA and microvascular complications of diabetes. Int J Endocrinol. 2018 6890501. 1-20
• 4 Armand-Labit V, Pradines A. Circulating cell-free microRNAs as clinical cancer biomarkers. Biomol Concepts 2017; 8: 61-81
• 5 Fehlmann T, Ludwig N, Backes C. et al. Distribution of microRNA biomarker candidates in solid tissues and body fluids. RNA Biol 2016; 13: 1084-1088
• 6 Ye EA, Steinle JJ. miR-146a suppresses STAT3/VEGF pathways and reduces apoptosis through IL-6 signaling in primary human retinal microvascular endothelial cells in high glucose conditions. Vision Res 2017; 139: 15-22
• 7 Shaker OG, Abdelaleem OO, Mahmoud RH. et al. Diagnostic and prognostic role of serum miR-20b, miR-17-3p, HOTAIR, and MALAT1 in diabetic retinopathy. IUBMB Life 2019; 71: 310-320
• 8 Zampetaki A, Willeit P, Burr S. et al. Angiogenic microRNAs linked to incidence and progression of diabetic retinopathy in type 1 diabetes. Diabetes. 2016; 65: 216-227
• 9 Joglekar MV, Januszewski AS, Jenkins AJ. et al. Circulating microRNA biomarkers of diabetic retinopathy. Diabetes 2016; 65: 22-24
• 10 Ragusa M, Caltabiano R, Russo A. et al. MicroRNAs in vitreus humor from patients with ocular diseases. Mol Vis 2013; 19: 430-440
• 11 Qin LL, An MX, Liu YL. et al. MicroRNA-126: A promising novel biomarker in peripheral blood for diabetic retinopathy. Int J Ophthalmol 2017; 10: 530-534
• 12 Fang S, Ma X, Guo S. et al. MicroRNA-126 inhibits cell viability and invasion in a diabetic retinopathy model via targeting IRS-1. Oncol Lett 2017; 14: 4311-4318
• 13 Liu HN, Cao NJ, Li X. et al. Serum microRNA-211 as a biomarker for diabetic retinopathy via modulating Sirtuin 1. Biochem Biophys Res Commun 2018; 505: 1236-1243
• 14 Zou HL, Wang Y, Gang Q. et al. Plasma level of miR-93 is associated with higher risk to develop type 2 diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2017; 255: 1159-1166
• 15 Hirota K, Keino H, Inoue M. et al. Comparisons of microRNA expression profiles in vitreous humor between eyes with macular hole and eyes with proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2015; 253: 335-342
• 16 Salam A, Mathew R, Sivaprasad S. Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta Ophthalmol 2011; 89: 405-411
• 17 Pastukh N, Meerson A, Kalish D. et al. Serum miR-122 levels correlate with diabetic retinopathy. Clin Exp Med 2019; 19: 255-260
• 18 Liu HN, Li X, Wu N. et al. Serum microRNA-221 as a biomarker for diabetic retinopathy in patients associated with type 2 diabetes. Int J Ophthalmol 2018; 11: 1889-1894
• 19 Mazzeo A, Beltramo E, Lopatina T. et al. Molecular and functional characterization of circulating extracellular vesicles from diabetic patients with and without retinopathy and healthy subjects. Exp Eye Res 2018; 176: 69-77
• 20 Liu R, Liu CM, Cui LL. et al. Expression and significance of MiR-126 and VEGF in proliferative diabetic retinopathy. Eur Rev Med Pharmacol Sci 2019; 23: 6387-6393
• 21 Mammadzada P, Bayle J, Gudmundsson J. et al. Identification of diagnostic and prognostic micrornas for recurrent vitreous hemorrhage in patients with proliferative diabetic retinopathy. J Clin Med. 2019 8. 1-14
• 22 Gong Q, Su G. Roles of miRNAs and long noncoding RNAs in the progression of diabetic retinopathy. Biosci Rep. 2017; 37: 1-18 doi: 10.1042/BSR20171157
• 23 Zhang J, Wu L, Chen J. et al. Downregulation of MicroRNA 29a/b exacerbated diabetic retinopathy by impairing the function of Muller cells via Forkhead box protein O4. Diab Vasc Dis Res 2018; 15: 214-222
• 24 Gomaa AR, Elsayed ET, Moftah RF. MicroRNA-200b Expression in the vitreous humor of patients with proliferative diabetic retinopathy. Ophthalmic Res 2017; 58: 168-175
• 25 Xiong F, Du X, Hu J. et al. Altered retinal microRNA expression profiles in early diabetic retinopathy: An in silico analysis. Curr Eye Res 2014; 39: 720-729
• 26 Natarajan R, Putta S, Kato M. MicroRNAs and diabetic complications. J Cardiovasc Transl Res 2012; 5: 413-422
• 27 Pearlstein DP, Ali MH, Mungai PT. et al. Role of mitochondrial oxidant generation in endothelial cell responses to hypoxia. Arterioscler Thromb Vasc Biol 2002; 22: 566-573
• 28 Yan SF, Ogawa S, Stern DM. et al. Hypoxia-induced modulation of endothelial cell properties: regulation of barrier function and expression of interleukin-6. Kidney Int 1997; 51: 419-425
• 29 Koto T, Takubo K, Ishida S. et al. Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells. Am J Pathol 2007; 170: 1389-1397
• 30 Ten VS, Pinsky DJ. Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction. Curr Opin Crit Care 2002; 8: 242-250
• 31 Han JA, Seo EY, Kim HJ. et al. Hypoxia-augmented constriction of deep femoral artery mediated by inhibition of eNOS in smooth muscle. Am J Physiol Cell Physiol 2013; 304: C78-C88
• 32 Garcia-Morales V, Friedrich J, Jorna LM. et al. The microRNA-7-mediated reduction in EPAC-1 contributes to vascular endothelial permeability and eNOS uncoupling in murine experimental retinopathy. Acta Diabetol 2017; 54: 581-591
• 33 Volpe CMO, Villar-Delfino PH, Dos Anjos PMF. et al. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis 2018; 9: 119
• 34 Kamalden TA, Macgregor-Das AM, Kannan SM. et al. Exosomal microRNA-15a transfer from the pancreas augments diabetic complications by inducing oxidative stress. Antioxid Redox Signal 2017; 27: 913-930
• 35 Li J, Hui L, Kang Q. et al. Down-regulation of microRNA-27b promotes retinal pigment epithelial cell proliferation and migration by targeting Nox2. Pathol Res Pract 2018; 214: 925-933
• 36 Nguyen TA, Park J, Dang TL. et al. Microprocessor depends on hemin to recognize the apical loop of primary microRNA. Nucleic Acids Res 2018; 46: 5726-5736
• 37 Li KK, Pang JC, Lau KM. et al. MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol 2013; 23: 413-425
• 38 Wang YG, Li L, Liu CH. et al. Peroxiredoxin 3 is resistant to oxidation-induced apoptosis of Hep-3b cells. Clin Transl Oncol 2014; 16: 561-566
• 39 Jiang Y, Sang Y, Qiu Q. microRNA-383 mediates high glucose-induced oxidative stress and apoptosis in retinal pigment epithelial cells by repressing peroxiredoxin 3. Am J Transl Res 2017; 9: 2374-2383
• 40 Nagaraja AK, Creighton CJ, Yu Z. et al. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 2010; 24: 447-463
• 41 Shi W, Alajez NM, Bastianutto C. et al. Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int J Cancer 2010; 126: 2036-2048
• 42 Satari M, Aghadavod E, Mobini M. et al. Association between miRNAs expression and signaling pathways of oxidative stress in diabetic retinopathy. J Cell Physiol 2019; 234: 8522-8532
• 43 Kong N, Lu X, Li B. Downregulation of microRNA-100 protects apoptosis and promotes neuronal growth in retinal ganglion cells. BMC Mol Biol 2014; 15: 25
• 44 Zhang R, Garrett Q, Zhou H. et al. Upregulation of miR-195 accelerates oxidative stress-induced retinal endothelial cell injury by targeting mitofusin 2 in diabetic rats. Mol Cell Endocrinol 2017; 452: 33-43
• 45 Zhong Q, Kowluru RA. Diabetic retinopathy and damage to mitochondrial structure and transport machinery. Invest Ophthalmol Vis Sci 2011; 52: 8739-8746
• 46 Murray AR, Chen Q, Takahashi Y. et al. MicroRNA-200b downregulates oxidation resistance 1 (Oxr1) expression in the retina of type 1 diabetes model. Invest Ophthalmol Vis Sci 2013; 54: 1689-1697
• 47 Wang J, Zhang J, Chen X. et al. miR-365 promotes diabetic retinopathy through inhibiting Timp3 and increasing oxidative stress. Exp Eye Res 2018; 168: 89-99
• 48 Chen P, Miao Y, Yan P. et al. MiR-455-5p ameliorates HG-induced apoptosis, oxidative stress and inflammatory via targeting SOCS3 in retinal pigment epithelial cells. J Cell Physiol 2019; 234: 21915-21924
• 49 Nejad C, Stunden HJ, Gantier MP. A guide to miRNAs in inflammation and innate immune responses. FEBS J 2018; 285: 3695-3716
• 50 Wang Q, Navitskaya S, Chakravarthy H. et al. Dual anti-inflammatory and anti-angiogenic action of miR-15a in diabetic retinopathy. EBioMedicine 2016; 11: 138-150
• 51 Opreanu M, Tikhonenko M, Bozack S. et al. The unconventional role of acid sphingomyelinase in regulation of retinal microangiopathy in diabetic human and animal models. Diabetes 2011; 60: 2370-2378
• 52 Shafabakhsh R, Aghadavod E, Mobini M. et al. Association between microRNAs expression and signaling pathways of inflammatory markers in diabetic retinopathy. J Cell Physiol 2019; 234: 7781-7787
• 53 Ye EA, Liu L, Jiang Y. et al. miR-15a/16 reduces retinal leukostasis through decreased pro-inflammatory signaling. J Neuroinflammation 2016; 13: 305
• 54 Li Y, VandenBoom TG, Wang Z. et al. Up-regulation of miR-146a contributes to the inhibition of invasion of pancreatic cancer cells. Cancer Res 2010; 70: 5703
• 55 Nahid MA, Satoh M, Chan EK. Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling. J Immunol 2011; 186: 1723-1734
• 56 Rippo MR, Olivieri F, Monsurro V. et al. MitomiRs in human inflamm-aging: a hypothesis involving miR-181a, miR-34a and miR-146a. Exp Gerontol 2014; 56: 154-163
• 57 Wang Q, Bozack SN, Yan Y. et al. Regulation of retinal inflammation by rhythmic expression of MiR-146a in diabetic retina. Invest Ophthalmol Vis Sci 2014; 55: 3986-3994
• 58 Ye EA, Steinle JJ. miR-146a attenuates inflammatory pathways mediated by TLR4/NF-kappaB and TNFalpha to protect primary human retinal microvascular endothelial cells grown in high glucose. Mediators Inflamm 2016; 2016: 3958453
• 59 Gorguner M, Cerci M, Gorguner I. Determination of adenosine deaminase activity and its isoenzymes for diagnosis of pleural effusions. Respirology 2000; 5: 321-324
• 60 Ungerer JP, Oosthuizen HM, Retief JH. et al. Significance of adenosine deaminase activity and its isoenzymes in tuberculous effusions. Chest 1994; 106: 33-37
• 61 Hoshino T, Yamada K, Masuoka K. et al. Elevated adenosine deaminase activity in the serum of patients with diabetes mellitus. Diabetes Res Clin Pract 1994; 25: 97-102
• 62 Fulzele S, El-Sherbini A, Ahmad S. et al. MicroRNA-146b-3p regulates retinal inflammation by suppressing adenosine deaminase-2 in diabetes. Biomed Res Int. 2015 846501. 1-8
• 63 Zhuang P, Muraleedharan CK, Xu S. Intraocular delivery of miR-146 inhibits diabetes-induced retinal functional defects in diabetic rat model. Invest Ophthalmol Vis Sci 2017; 58: 1646-1655
• 64 Poliseno L, Tuccoli A, Mariani L. et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006; 108: 3068-3071
• 65 Kuehbacher A, Urbich C, Zeiher AM. et al. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 2007; 101: 59-68
• 66 Chang SH, Hla T. Gene regulation by RNA binding proteins and microRNAs in angiogenesis. Trends Mol Med 2011; 17: 650-658
• 67 Ribatti D, Conconi MT, Nussdorfer GG. Nonclassic endogenous novel [corrected] regulators of angiogenesis. Pharmacol Rev 2007; 59: 185-205
• 68 Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: Insights from physiological angiogenesis. Nat Rev Cancer 2010; 10: 505-514
• 69 Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307
• 70 Wu F, Yang Z, Li G. Role of specific microRNAs for endothelial function and angiogenesis. Biochem Biophys Res Commun 2009; 386: 549-553
• 71 van Solingen C, Bijkerk R, de Boer HC. et al. The role of microRNA-126 in vascular homeostasis. Curr Vasc Pharmacol 2015; 13: 341-351
• 72 Li EH, Huang QZ, Li GC. et al. Effects of miRNA-200b on the development of diabetic retinopathy by targeting VEGFA gene. Biosci Rep. 2017; 37: 1-25 10.1042/BSR20160572
• 73 Yin KJ, Olsen K, Hamblin M. et al. Vascular endothelial cell-specific microRNA-15a inhibits angiogenesis in hindlimb ischemia. J Biol Chem 2012; 287: 27055-27064
• 74 Hua Z, Lv Q, Ye W. et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006; 1: e116
• 75 Kao HW, Pan CY, Lai CH. et al. Urine miR-21-5p as a potential non-invasive biomarker for gastric cancer. Oncotarget 2017; 8: 56389-56397
• 76 Qu K, Zhang X, Lin T. et al. Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation. Sci Rep 2017; 7: 1692
• 77 Matsuzaki K, Fujita K, Jingushi K. et al. MiR-21-5p in urinary extracellular vesicles is a novel biomarker of urothelial carcinoma. Oncotarget 2017; 8: 24668-24678
• 78 Jiang Q, Lyu XM, Yuan Y. et al. Plasma miR-21 expression: An indicator for the severity of Type 2 diabetes with diabetic retinopathy. Biosci Rep. 2017; 37: 1-4 10.1042/BSR20160589
• 79 Qiu F, Tong H, Wang Y. et al. Inhibition of miR-21-5p suppresses high glucose-induced proliferation and angiogenesis of human retinal microvascular endothelial cells by the regulation of AKT and ERK pathways via maspin. Biosci Biotechnol Biochem 2018; 82: 1366-1376
• 80 Chen B, Chen X, Wu X. et al. Disruption of microRNA-21 by TALEN leads to diminished cell transformation and increased expression of cell-environment interaction genes. Cancer Lett 2015; 356: 506-516
• 81 Caporali A, Emanueli C. MicroRNA regulation in angiogenesis. Vascul Pharmacol 2011; 55: 79-86
• 82 van Rooij E, Marshall WS, Olson EN. Toward microRNA-based therapeutics for heart disease: The sense in antisense. Circ Res 2008; 103: 919-928
• 83 Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol 2016; 231: 25-30
• 84 Zhang J, Cui C, Xu H. Downregulation of miR-145-5p elevates retinal ganglion cell survival to delay diabetic retinopathy progress by targeting FGF5. Biosci Biotechnol Biochem 2019; 83: 1655-1662
• 85 Zhang ZZ, Qin XH, Zhang J. MicroRNA-183 inhibition exerts suppressive effects on diabetic retinopathy by inactivating BTG1-mediated PI3K/Akt/VEGF signaling pathway. Am J Physiol Endocrinol Metab 2019; 316: E1050-E1060
• 86 Chen C, Zhao C, Gu C. et al. MiRNA-144-3p inhibits high glucose induced cell proliferation through suppressing FGF16. Biosci Rep. 2019; 39: 6-6 10.1042/BSR20181788
• 87 Xia F, Sun JJ, Jiang YQ. et al. MicroRNA-384-3p inhibits retinal neovascularization through targeting hexokinase 2 in mice with diabetic retinopathy. J Cell Physiol 2018; 234: 721-730